• Contact Us

  • Pipeline
    NM002 (Nylexa®) for COVID 19 NM002 (Nylexa®) for AMR NM001 (Lynovex®) NP339 for Invasive Fungal Disease NP339 for Respiratory Fungal Disease NP213 (Novexatin®)) NP432

  • Technology

  • Therapeutic Focus

  • About Us
    Board and Management Investors Corporate Social Responsibility

  • News and Events
  • Follow
  • Follow
  • Follow
  • News and Events
  • Therapeutic Focus
  • About Us
    • Board and Management
    • Investors
    • Corporate Social Responsibility
  • Technology
  • Pipeline
    • NM002 (Nylexa®) for COVID19
    • NM002 (Nylexa®) for AMR
    • NM001 (Lynovex®)
    • NP339 for Invasive Fungal Disease
    • NP339 for Respiratory Fungal Disease
    • NP213 (Novexatin®)
    • NP432
  • Contact Us

Lynovex Poster Presentations at 33rd North American Cystic Fibrosis Conference (NACFC)

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 Three Posters on New Lynovex Preclinical and Clinical Data to be presented at NACFC, 31st October to 2nd November 2019, Nashville Tennessee. Dr Douglas Fraser-Pitt will present three posters on Thursday 31st October 2019...

NovaBiotics Prize awarded at Robert Gordon University Ceremony

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 Congratulations to Amanda Nicolson, winner of the Novabiotics Prize: Best IBMS Registration Training Portfolio at the 11th July 2019 prize-giving ceremony held at Robert Gordon University, Garthdee Campus in Aberdeen. Categories Press...

NovaBiotics to present new data on their novel Cystic Fibrosis drugs at the European CF Society’s Annual Conference

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 NovaBiotics will present new efficacy data for their Lynovex® Cystic Fibrosis (CF) drug candidates at the European CF Society Conference (ECFS) in Liverpool, UK, June 5th-8th. ECFS is a major international event and provides a forum for all...

NovaBiotics presenting new data at European Cystic Fibrosis Conference

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 NovaBiotics are pleased to announce that we will be participating in the 42nd European Cystic Fibrosis Conference (ECFS); 5-8 June 2019, Liverpool. Our team will be presenting exciting new data on the antimicrobial mechanism of action,...

Novexatin manuscript published in Antimicrobial Agents & Chemotherapy Journal

by novabioticsadm1n | Mar 19, 2019 | 2019, Press Releases

Date posted: March 19, 2020 The manuscript is entitled “Improved Methods for Assessing Therapeutic Potential of Antifungal Agents Against Dermatophytes and their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate”. The...

Recent Posts

  • Clear and unbiased facts about why the COVID 19/Pneumonia relationship is bad news
  • Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
  • NovaBiotics Attending BIO CEO & Investor Digital Conference
  • Just when we thought things were getting better…..
  • CARE CF 1 oral Lynovex clinical trial data published

Recent Comments

    NovaBiotics Ltd
    Silverburn Crescent
    Bridge of Don
    Aberdeen
    AB23 8EW, UK

    Tel:+44 (0)1224 711377

    Registered Company
    No. SC272344

    NovaBiotics Inc
    One Boston Place,
    Suite 2600,
    Boston
    MA, 02108

    Tel:+1 866 259 4527

    NovaBiotics
    90 Upper George's Street,
    Dun Laoghaire,
    Co. Dublin,
    A96 R8R9

    Tel:+353 1 2712605

    Registered Company
    No. 642058

    News and Events

    About Us

    Therapeutic Focus

    Technology

    Pipeline

    Contact Us